Audentes Therapeutics (BOLD) Rating Increased to Buy at ValuEngine

Audentes Therapeutics (NASDAQ:BOLD) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Friday.

Several other brokerages have also commented on BOLD. Zacks Investment Research lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub upgraded Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 6th. William Blair restated a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, February 27th. Chardan Capital upgraded Audentes Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $35.00 to $40.00 in a research note on Monday, February 25th. Finally, HC Wainwright restated a “buy” rating and set a $33.00 price target on shares of Audentes Therapeutics in a research note on Friday, January 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $33.39.

NASDAQ:BOLD traded up $1.53 on Friday, hitting $38.19. 668,490 shares of the stock were exchanged, compared to its average volume of 527,693. The firm has a market capitalization of $1.52 billion, a PE ratio of -11.23 and a beta of 1.90. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.91) by $0.07. During the same period last year, the business earned ($0.82) EPS. As a group, research analysts predict that Audentes Therapeutics will post -3.85 EPS for the current year.

In other news, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.06, for a total value of $300,600.00. Following the completion of the sale, the vice president now owns 28,236 shares of the company’s stock, valued at $848,774.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Louis G. Lange sold 32,000 shares of the company’s stock in a transaction dated Monday, December 24th. The stock was sold at an average price of $18.62, for a total value of $595,840.00. Following the completion of the sale, the director now directly owns 325,799 shares of the company’s stock, valued at approximately $6,066,377.38. The disclosure for this sale can be found here. Insiders sold 63,000 shares of company stock valued at $1,526,440 in the last ninety days. Company insiders own 6.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of BOLD. Bank of New York Mellon Corp boosted its position in Audentes Therapeutics by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 127,693 shares of the biotechnology company’s stock valued at $4,879,000 after buying an additional 31,048 shares during the period. Wells Fargo & Company MN raised its holdings in Audentes Therapeutics by 7.9% in the 3rd quarter. Wells Fargo & Company MN now owns 429,678 shares of the biotechnology company’s stock worth $17,011,000 after purchasing an additional 31,523 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Audentes Therapeutics by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 117,284 shares of the biotechnology company’s stock worth $4,644,000 after purchasing an additional 3,331 shares in the last quarter. Candriam Luxembourg S.C.A. raised its holdings in Audentes Therapeutics by 243.6% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 238,800 shares of the biotechnology company’s stock worth $9,454,000 after purchasing an additional 169,300 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Audentes Therapeutics by 0.8% in the 3rd quarter. Jennison Associates LLC now owns 1,028,668 shares of the biotechnology company’s stock worth $40,725,000 after purchasing an additional 8,112 shares in the last quarter.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: What is insider trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.